These data suggest that increased CD44 or SLC16A1 expression is a probable prognostic marker in pancreatic cancer patients and is related to tumor aggressiveness mediated by metabolic reprogramming, CSC phenotype, and rapid cell proliferation. Here, CD44 is linked to familial pancreatic carcinoma.